摘要
目的观察瑞舒伐他汀联合参附注射液在老年慢性心力衰竭中的临床疗效。方法选取2018年4月至2019年3月在本院治疗的104例老年慢性心力衰竭患者作为研究对象,采用双色球法分为A组和B组,各52例。A组采用参附注射液治疗,B组采用瑞舒伐他汀+参附注射液治疗,比较两组临床疗效、C反应蛋白(CRP)、降钙素原(PCT)。结果B组患者临床治疗总有效率显著高于A组;治疗后,B组患者的CRP、PCT均低于A组,两组比较差异具有统计学意义(P<0.05)。结论在老年慢性心力衰竭中应用瑞舒伐他汀联合参附注射液,临床效果显著,能够对机体炎症反应进行有效抑制,值得临床推广。
Objective To observe the clinical efficacy of rosuvastatin combined with Shenfu injection in elderly patients with chronic heart failure.Methods 104 elderly patients with chronic heart failure who were treated in our hospital from April 2018 to March 2019 were enrolled.They were divided into group A and group B by two-color ball method,with 52 cases in each group.Group A was treated with Shenfu injection.Group B was treated with rosuvastatin+Shenfu injection,and the clinical efficacy,C-reactive protein(CRP)and procalcitonin(PCT)were compared between the two groups.Results The total effective rate of clinical treatment in group B was significantly higher than that in group A.After treatment,the CRP and PCT of group B were lower than those of group A.The difference was statistically significant between the two groups(P<0.05).Conclusion The application of rosuvastatin combined with Shenfu injection in elderly patients with chronic heart failure has significant clinical effects and can effectively inhibit the body's inflammatory response,which is worthy of promotion.
作者
刘宏明
Liu Hongming(Department of Pharmacy,Ganzhou City People's Hospital of Jiangxi Province,Ganzhou,Jiangxi,341000,China)
出处
《当代医学》
2020年第13期9-11,共3页
Contemporary Medicine
